.jpg)
.png)
Summer 2018
This issue sponsored by the Midwest Lipid Association Featuring: "A National Lipid Association Best Practices Guide: PCSK9 Inhibitors"
The National Lipid Association has been quite busy since the 2018 Scientific Sessions in Las Vegas. Below are some of the recent highlights. Stay tuned for more recurring updates from our organization. Guidelines Dissemination Task Force With the anticipated November 2018 release of the 2018... more
Greetings from those of us at the Midwest Lipid Association (MWLA). We all trust that you had an excellent summer as we head into cooler weather and color changes up here in the Midwest and Canada. For those of you who do not know, our Canadian partners who are National Lipid Association (NLA)... more
Our healthcare organization has designated “population health management” as a core part of our strategy planning and accountability. This is reflected through the implementation of what is defined as the “quadruple aim:” –providing health care which is affordable,... more
What is the Structure of Lp(a)? Lipoprotein(a) [Lp(a)] was first described as an antigenic variant of low-density lipoprotein (LDL) in 1963.1 Indeed, Lp(a) contains an LDL-like moiety but is distinguished by the attached unique protein apolipoprotein(a) [apo(a)]. (Fig. 1) Apo(a) confers unique... more
Lipodystrophies are a group of disorders of fat tissue loss that are classified according to whether the condition is genetic or acquired and by the distribution of fat loss, either generalized or partial (Table 1).1 Generalized lipodystrophy is a rare, complex, and clinically heterogeneous... more
COMMITTEE NOTE TO MEMBERS OF THE NATIONAL LIPID ASSOCIATION: At the request of the NLA President, the NLA Board of Directors, the Science and Policy Council, the Practice Management Council and the Health Quality and Research Committee, it is with pleasure that the 2017-18 NLA Therapeutics... more
Volanesorsen is a novel pharmacotherapy designed to treat patients with Familial Chylomicronemia Syndrome (FCS). This is a highly comorbid disease without any currently available pharmacotherapies to help reduce triglycerides or the more feared complication, pancreatitis. This has left a void in... more
Background The random occurrence of heart attacks and strokes has always posed a medical challenge. Despite the association of circadian rhythm with increased incidence of cardiovascular events in the early morning hours, and triggers such as anger and emotional distress, the occurrence... more
The Midwest Lipid Association is 510 members strong and represents Indiana, Illinois, Wisconsin, Michigan, Ohio, Kansas, Iowa, Missouri, North Dakota, South Dakota, Minnesota and Nebraska. We are pleased to have David R. Neff, DO, FNLA, serving as our President this year. We have an active and... more